AstraZeneca to return sepsis drug to BTG after Phase IIb failure
This article was originally published in Scrip
Executive Summary
AstraZeneca has decided to stop further development of AZD9773 (CytoFab) for the treatment of severe sepsis and/or septic shock, and will hand the asset back to BTG as it failed to show any significant improvements versus placebo in a Phase IIb study, BTG has announced.